Sex: a major predictor of remission in early rheumatoid arthritis? - PubMed (original) (raw)
Sex: a major predictor of remission in early rheumatoid arthritis?
K Forslind et al. Ann Rheum Dis. 2007 Jan.
Abstract
Background: The treatment goal of early rheumatoid arthritis is remission. This study reports remission rates in clinical practice using a cohort of patients with early rheumatoid arthritis.
Methods: 698 patients with early rheumatoid arthritis were included. Mean age at inclusion was 58 years and mean disease duration was 6.4 months; 64% of the patients were women, 56% were positive for antibodies to cyclic citrullinated peptide and 60% were positive for rheumatoid factor. Remission was defined as a disease activity score <2.6, with or without ongoing treatment with drugs for rheumatoid arthritis.
Results: After 2 years, 261 of 689 patients were in remission (37.9%), and after 5 years, the remission rate was 38.5%. However, only 26.1% were in remission at both these time points. Multiple logistic regression analyses found sex to be a main predictor for remission. Thus, significantly fewer women were in remission after 2 years (32.1% v 48%, p = 0.001) after 5 years (30.8% v 52.4%, p = 0.001) and at both these time points (19.1% v 39.3%, p = 0.001). Although disease activity was not with certainty more pronounced in women at onset of disease, the disease course became markedly worse in women. The disparity in remission frequency between women and men could not be explained by differences in disease duration, age or treatment with disease modifying antirheumatic drugs or glucocorticoids.
Conclusions: Early remission of rheumatoid arthritis by 28-joint Disease Activity Score<2.6 was as frequent or more frequent in this study than in most previous reports. Importantly, women had more severe disease with a considerably lower remission rate than men, although the disease activity before treatment seemed similar.
Conflict of interest statement
Competing interests: None declared.
Similar articles
- Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.
Hetland ML, Haavardsholm EA, Rudin A, Nordström D, Nurmohamed M, Gudbjornsson B, Lampa J, Hørslev-Petersen K, Uhlig T, Grondal G, Østergaard M, Heiberg MS, Twisk J, Lend K, Krabbe S, Hyldstrup LH, Lindqvist J, Hultgård Ekwall AK, Grøn KL, Kapetanovic M, Faustini F, Tuompo R, Lorenzen T, Cagnotto G, Baecklund E, Hendricks O, Vedder D, Sokka-Isler T, Husmark T, Ljoså MA, Brodin E, Ellingsen T, Söderbergh A, Rizk M, Olsson ÅR, Larsson P, Uhrenholt L, Just SA, Stevens DJ, Laurberg TB, Bakland G, Olsen IC, van Vollenhoven R; NORD-STAR study group. Hetland ML, et al. BMJ. 2020 Dec 2;371:m4328. doi: 10.1136/bmj.m4328. BMJ. 2020. PMID: 33268527 Free PMC article. Clinical Trial. - Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
Rannio T, Asikainen J, Hannonen P, Yli-Kerttula T, Ekman P, Pirilä L, Kuusalo L, Mali M, Puurtinen-Vilkki M, Kortelainen S, Paltta J, Taimen K, Kauppi M, Laiho K, Nyrhinen S, Mäkinen H, Isomäki P, Uotila T, Aaltonen K, Kautiainen H, Sokka T. Rannio T, et al. Scand J Rheumatol. 2017 Nov;46(6):425-431. doi: 10.1080/03009742.2016.1266029. Epub 2017 Apr 3. Scand J Rheumatol. 2017. PMID: 28367663 - Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the PREDICT study.
Bird P, Nicholls D, Barrett R, de Jager J, Griffiths H, Roberts L, Tymms K, McCloud P, Littlejohn G; OPAL consortium. Bird P, et al. Int J Rheum Dis. 2017 Apr;20(4):460-468. doi: 10.1111/1756-185X.13036. Epub 2017 Feb 16. Int J Rheum Dis. 2017. PMID: 28205333 - Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
Verhoef LM, van den Bemt BJ, van der Maas A, Vriezekolk JE, Hulscher ME, van den Hoogen FH, Jacobs WC, van Herwaarden N, den Broeder AA. Verhoef LM, et al. Cochrane Database Syst Rev. 2019 May 24;5(5):CD010455. doi: 10.1002/14651858.CD010455.pub3. Cochrane Database Syst Rev. 2019. PMID: 31125448 Free PMC article. - Clinical outcome measures in rheumatoid arthritis.
van Riel PL, van Gestel AM. van Riel PL, et al. Ann Rheum Dis. 2000 Nov;59 Suppl 1(Suppl 1):i28-31. doi: 10.1136/ard.59.suppl_1.i28. Ann Rheum Dis. 2000. PMID: 11053082 Free PMC article. Review. No abstract available.
Cited by
- Locating sex-specific evidence on clinical questions in MEDLINE: a search filter for use on OvidSP.
Moerman CJ, Deurenberg R, Haafkens JA. Moerman CJ, et al. BMC Med Res Methodol. 2009 Apr 14;9:25. doi: 10.1186/1471-2288-9-25. BMC Med Res Methodol. 2009. PMID: 19366443 Free PMC article. - Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study.
Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, Skakic V, Badsha H, Peets T, Baranauskaite A, Géher P, Ujfalussy I, Skopouli FN, Mavrommati M, Alten R, Pohl C, Sibilia J, Stancati A, Salaffi F, Romanowski W, Zarowny-Wierzbinska D, Henrohn D, Bresnihan B, Minnock P, Knudsen LS, Jacobs JW, Calvo-Alen J, Lazovskis J, Pinheiro Gda R, Karateev D, Andersone D, Rexhepi S, Yazici Y, Pincus T; QUEST-RA Group. Sokka T, et al. Arthritis Res Ther. 2009;11(1):R7. doi: 10.1186/ar2591. Epub 2009 Jan 14. Arthritis Res Ther. 2009. PMID: 19144159 Free PMC article. - Long-term sustained remission in a cohort study of patients with rheumatoid arthritis: choice of remission criteria.
Svensson B, Andersson ML, Bala SV, Forslind K, Hafström I; BARFOT study group. Svensson B, et al. BMJ Open. 2013 Sep 10;3(9):e003554. doi: 10.1136/bmjopen-2013-003554. BMJ Open. 2013. PMID: 24022393 Free PMC article. - Association of body fat with C-reactive protein in rheumatoid arthritis.
Giles JT, Bartlett SJ, Andersen R, Thompson R, Fontaine KR, Bathon JM. Giles JT, et al. Arthritis Rheum. 2008 Sep;58(9):2632-41. doi: 10.1002/art.23766. Arthritis Rheum. 2008. PMID: 18759279 Free PMC article. - Polymorphisms in the glucocorticoid receptor gene and in the glucocorticoid-induced transcript 1 gene are associated with disease activity and response to glucocorticoid bridging therapy in rheumatoid arthritis.
Quax RA, Koper JW, Huisman AM, Weel A, Hazes JM, Lamberts SW, Feelders RA. Quax RA, et al. Rheumatol Int. 2015 Aug;35(8):1325-33. doi: 10.1007/s00296-015-3235-z. Epub 2015 Feb 28. Rheumatol Int. 2015. PMID: 25724472 Free PMC article.
References
- EULAR handbook of clinical assessments in rheumatoid arthritis The Netherlands: van Zuiden Communications BV 2000
- Prevoo M L, van Gestel A M, van' t Hof M A, van Rijswijk M H, van de Putte L B, van Riel P L. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the Disease Activity Score. Br J Rheumatol 1996351101–1105. - PubMed
- Pinals R S, Masi A T, Larsen R A, and the subcommittee for criteria of remission in rheumatoid arthritis of the American Rheumatism Association diagnostic and therapeutic criteria committee Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981241308–1315. - PubMed
- Svensson B, Schaufelberger C, Teleman A, Theander J. Remission and response to early treatment of RA assessed by the Disease Activity Score. Rheumatology 2000391031–1036. - PubMed
- Balsa A, Carmona L, Gonzales‐Alvaro I, Belmonte M A, Tena X, Sanmarti R for the EMECAR Study Group Value of Disease Activity Score 28 (DAS28) and DAS28‐3 compared to American College of Rheumatology‐defined remission in rheumatoid arthritis. J Rheumatol 20043140–46. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical